Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

Mazur, 1983, Gastric stromal tumors, Reappraisal of histogenesis. Am J Surg Pathol, 7, 507, 10.1097/00000478-198309000-00001 Schaldenbrand, 1984, Solitary solid stromal gastrointestinal tumors in von Recklinghausen's disease with minimal smooth muscle differentiation, Hum Pathol, 15, 229, 10.1016/S0046-8177(84)80184-7 Nishida, 1998, Familial gastrointestinal stromal tumours with germline mutations of the KIT gene, Nat Genet, 19, 323, 10.1038/1209 Miettinen, 1999, Gastrointestinal stromal tumors: recent advances in understanding of their biology, Hum Pathol, 30, 1213, 10.1016/S0046-8177(99)90040-0 Nishida, 2000, Biological and clinical review of stromal tumors in the gastrointestinal tract, Histol Histopathol, 15, 1293 Rubin, 2000, Molecular insights into the histogenesis and pathogenesis of gastrointestinal tumors, Int J Surg Pathol, 8, 5, 10.1177/106689690000800105 Fletcher, 2002, Diagnosis of gastrointestinal stromal tumors: a consensus approach, Hum Pathol, 33, 459, 10.1053/hupa.2002.123545 van Oosterom, 1995, New drugs for the treatment of sarcomas, Hematol Oncol Clin North Am, 9, 909, 10.1016/S0889-8588(18)30078-9 Plaat, 2000, Soft tissue leiomyosarcomas and malignant gastrointestinal tumors: differences in clinical outcome and expression of multidrug resistance proteins, J Clin Oncol, 18, 3211, 10.1200/JCO.2000.18.18.3211 Ryan, 2002, A phase II and pharmacokinetic study of ET743 in patients with gastrointestinal stromal tumors, Oncologist, 7, 531, 10.1634/theoncologist.7-6-531 Blay, 2004, A phase II study of ET-743/trabectedin (‘Yondelis’) for patients with advanced gastrointestinal stromal tumours, Eur J Cancer, 40, 1327, 10.1016/j.ejca.2004.02.005 Emory, 1999, Prognosis of gastrointestinal smooth-muscle (stromal) tumors: Dependence on anatomic site, Am J Surg Pathol, 23, 82, 10.1097/00000478-199901000-00009 Joensuu, 2001, Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor, N Engl J Med, 344, 1052, 10.1056/NEJM200104053441404 van Oosterom, 2001, Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study, Lancet, 358, 1421, 10.1016/S0140-6736(01)06535-7 Demetri, 2002, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors, N Engl J Med, 347, 472, 10.1056/NEJMoa020461 Verweij, 2003, Eur J Cancer, 39, 2006, 10.1016/S0959-8049(02)00836-5 Verweij, 2004, Improved progression free survival in gastro-intestinal stromal tumors with high dose Imatinib. Results of a randomized phase III study of the EORTC, ISG and AGITG, Lancet, 364, 1127, 10.1016/S0140-6736(04)17098-0 Rankin, 2004, Continued prolongation of survival by imatinib in patients with metastatic GIST Update of results from North American Intergroup phase III study S0033, Proc Am Soc Clin Oncol, 23, 815 Blay, 2004, Continuous vs intermittent imatinib treatment in advanced GIST after one year A prospective randomized phase III trial of the French Sarcoma Group, Proc Am Soc Clin Oncol, 23 Demetri, 2004, Optimal management of patients with Gastrintesinal stromal tumors. Expansion and update of NCCN Clinical Practice Guidelines, JNCCN, 2 Kindblom, 2003, Meis KindBlom J, Bumming P et al. Incdnce, prevalence, phenotype and biologic spectrum of gastrointestinal stromal tumors (GIST): a population-based study of 600 cases, Ann Oncol, 13, 157 Emile, 2002, Length analysis of polymerase chain reaction products: a sensitive and reliable technique for the detection of mutations in KIT exon 11 in gastrointestinal stromal tumors, Diagn Mol Pathol, 11, 107, 10.1097/00019606-200206000-00007 Emile, 2004, Clinicopathological, phenotypic and genotypic characteristics of gastrointestinal mesenchymal tumors, Clin Gastroenterol Hepatol, 2, 597, 10.1016/S1542-3565(04)00243-5 Corless, 2002, KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size, Am J Pathol, 160, 1567, 10.1016/S0002-9440(10)61103-0 Heinrich, 2003, Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor, J Clin Oncol, 21, 4342, 10.1200/JCO.2003.04.190 Debiec-Rychter, 2004, Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group, Eur J Cancer, 40, 689, 10.1016/j.ejca.2003.11.025 Xiao, 2001, Denaturing high-performance liquid chromatography: A review, Hum Mutat, 17, 439, 10.1002/humu.1130 Eng-Hen, 1992, Prognostic factors influencing survival in gastro-intestinal leiomyosarcoma, Ann Surg, 215, 68, 10.1097/00000658-199201000-00010 DeMatteo, 2000, Two hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival, Ann Surg, 231, 51, 10.1097/00000658-200001000-00008 DeMatteo, 2002, Clinical management of gastrointestinal stromal tumors: before and after STI-571, Hum Pathol, 33, 466, 10.1053/hupa.2002.124122 Dagher, 2002, Report from the FDA. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors, Clin Cancer Res, 8, 3034 Ng, 1992, Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging, Ann Surg, 215, 68, 10.1097/00000658-199201000-00010 Van den Abbeele, 2002, 18F-FDG-PET predicts response to imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST), Proc Am Soc Clin Oncol, 21, 403a Stroobants, 2003, 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Imatinib), Eur J Cancer, 39, 2012, 10.1016/S0959-8049(03)00073-X Janicek, 2002, Does pattern of metastases and early measurable changes after treatment predict therapy effect in gastrointestinal stromal tumor (GIST) on STI571 (Imatinib)? Chicago, IL: RSNA 2002 Scientific, Program, 583 Choi, 2002, Monitoring treatment effects of STI-571 on gastrointestinal stomal tumors (GIST) with CT and PET: a quantitative analysis. Chicago, IL: RSNA 2002 Scientific, Program, 583 Jager, 2004, Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET, Nucl Med Commun, 25, 433, 10.1097/00006231-200405000-00002 Antoch, 2004, Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors, J Nucl Med, 45, 357 Choi, 2003, Correlation of computerized tomography (CT) and proton emission tomography (PET) in patients with metastatic GIST treated at a single institution with imatinib mesylate, Proc Am Soc Clin Oncol, 22, 819 Heinrich, 2003, Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor, J Clin Oncol, 21, 4342, 10.1200/JCO.2003.04.190 Debiec-Rychter, 2004, Eur J Cancer, 40, 689, 10.1016/j.ejca.2003.11.025 Corless, 2004, Biology of gastrointestinal stromal tumors, J Clin Oncol, 22, 3813, 10.1200/JCO.2004.05.140 Bauer, 2004, Imatinib may enable complete resection in previously unresectable or metastatic GIST, Proc Am Soc Clin Oncol, 23, 819 Dileo, 2004, Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM), Proc Am Soc Clin Oncol, 23, 818 JZalcberg, 2004, Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800mg (HD) after progression on 400mg (LD)—an international intergroup study of the EORTC ISG and AGITG, Proc Am Soc Clin Oncol, 23, 815 Demetri, 2004, SU11248 a multi-targeted tyrosine kinase inhibitor can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST), Proc Am Soc Clin Oncol, 23, 195 1993, WHO/ISH Mild Hypertension Liaison Committee. Summary of the World Health Organisation–International Society of Hypertension guidelines for the management of mild hypertension, BMJ, 307, 1541, 10.1136/bmj.307.6918.1541 Berg, 1997, Clinical practice guidelines in practice and education, J Gen Intern Med, 12, S25, 10.1046/j.1525-1497.12.s2.4.x Schriefer, 1994, The synergy of pathways and algorithms: Two tools work better than one, Jt Comm J Qual Improve, 20, 485, 10.1016/S1070-3241(16)30095-5 1995 McKee, 1995, Guidelines, enthusiasms, uncertainty, and limits to purchasing, BMJ, 310, 101, 10.1136/bmj.310.6972.101 Morrison, 2001, Pragmatic randomized controlled trial to evaluate guidelines for the management of infertility across the primary-secondary care interface, BMJ, 322, 1282, 10.1136/bmj.322.7297.1282 Pauly, 1995, Practice guidelines: Can they save money? Should they?, J Law Med Ethics, 23, 65, 10.1111/j.1748-720X.1995.tb01333.x Carpenter, 1993, Evaluating the cost containment of potential clinical guidelines, Qual Rev Bull, 19, 119, 10.1016/S0097-5990(16)30604-2 Merlani, 2001, Linking guideline to regular feedback to increase appropriate requests for clinical tests: Blood gas analysis in intensive care, BMJ, 323, 620, 10.1136/bmj.323.7313.620 Granata, 1998, Competing practice guidelines: Using cost-effectiveness analysis to make optimal decisions, Ann Intern Med, 128, 56, 10.7326/0003-4819-128-1-199801010-00009 Gross, 2000, Implementing evidence-based recommendations for health care: a roundtable comparing European and American experiences, Jt Comm J Qual Improv, 26, 547 Demetri, 2004, SU11248 a multi-targeted tyrosine kinase inhibitor can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST), Proc Am Soc Clin Oncol, 23, 816 Grimshaw, 1993, Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations, Lancet, 342, 1317, 10.1016/0140-6736(93)92244-N Ray-Coquard, 2004, Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas, Ann Oncol, 15, 307, 10.1093/annonc/mdh058